Remacemide Hydrochloride | Zendy

Alexander Dyker | Zendy; Kennedy R. Lees | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Remacemide Hydrochloride

Author(s) -

Alexander Dyker,

Kennedy R. Lees

Publication year - 1999

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.30.9.1796

Subject(s) - medicine , tolerability , placebo , adverse effect , stroke (engine) , anesthesia , neuroprotection , pharmacology , pharmacokinetics , hydrochloride , mechanical engineering , alternative medicine , pathology , engineering , chemistry , organic chemistry

Remacemide hydrochloride and its principal active desglycinyl metabolite are low-affinity noncompetitive N-methyl-D-aspartate (NMDA)-receptor channel blockers. Remacemide hydrochloride has demonstrated neuroprotection in animal models of hypoxia and ischemic stroke. This study assessed the safety, tolerability, and pharmacokinetics of ascending doses of remacemide hydrochloride in patients with recent onset (within 12 hours) ischemic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research